G-Biotec

G-Biotec is a South Korean biotechnology company dedicated to developing first-in-class therapeutics for muscle-related diseases and metabolic disorders. Founded by Professor Gyu-Un Bae, the company leverages deep expertise in myogenesis and muscle regeneration to address conditions such as sarcopenia, cancer cachexia, and obesity. Its lead candidate, GB-101, is a small molecule designed to promote muscle cell differentiation and is currently being evaluated for the treatment of muscle atrophy. G-Biotec's research platform focuses on identifying novel molecular targets that regulate the growth and repair of skeletal muscle. The company aims to provide innovative solutions for the growing global burden of aging-related musculoskeletal decline.